Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...
William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...
Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...
TipRanks on MSN
Amgen price target raised to $372 from $335 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Amgen (AMGN) to $372 from $335 and keeps an Outperform rating on the shares.
Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:45 PM ESTCompany ParticipantsPeter Griffith - Executive VP & ...
After showing a lack of direction early in the session, stocks moved mostly higher over the course of the trading day on Wednesday. While the Nasdaq and the S&P 500 posted ...
Live Updates Get The Best SPDR S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on SPDR S&P 500 ETF, market updates, and brand-new stock ...
Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback